|
|
Introduction |
Under the belief that "the
elimination of disease will be
started from the prevention,"
Green Cross started the vaccine
business at the end of 1960s.
Based on the long established
experience, Green Cross succeeded
in developing the world's third
Hepatitis B vaccine in 1983 followed
by the world's first Epidemic
Hemorrhagic Fever vaccine in 1988
and the world's second Chicken
Pox vaccine in 1988. Particularly,
'Hepavax', a Hepatitis B vaccine,
decisively contributed to the
national health by reducing half
the Hepatitis B virus carrier
rate that had been reached 13%.
'Hepavax' of 400 million doses,
the quantity 130 million people
can be vaccinated, have been distributed
to 60 countries and the international
organization such as WHO, UNICEF
and PAHO. Green Cross Vaccine Corp., vaccine unit spun off from Green Cross in 1988, is now a subsidiary of Berna Biotech through a strategic alliance with Rhein Biotech of Germany in 2000 and acquisition of Rhein Biotech from Berna Biotech of Switzerland in 2002.
Green Cross took over such vaccine lines as those for chicken pox and epidemic hemorrhagic fever from Berna Biotech in 2005. The company has resumed a full-scale vaccine business by setting up ‘Green Cross Vaccine Co., specializing in vaccine development, while constructing an influenza vaccine plant in Hwasun, Jeonnam.
|
|
|
